Regulatory Approval Granted for Reformulated Ranitidine
Contributed By : Medical Dialogues Team
Published On 2026-01-29 04:30 GMT | Update On 2026-01-29 08:51 GMT
Advertisement
The U.S. FDA has approved reformulated ranitidine tablets, marking the reintroduction of this widely used H2 receptor antagonist following extensive regulatory review and updated safety assessments, alongside its continued inclusion in the WHO Essential Medicines List. This video highlights key global regulatory developments, including approvals in other regions, the continued inclusion of ranitidine in the WHO Essential Medicines List, and its ongoing clinical relevance in the management of acid-related disorders such as GERD and peptic ulcer disease.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.